|
| Press Releases |
|
 |
|
| Tuesday, December 6, 2022 |
|
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research (A*STAR); National University of Singapore (NUS); Nanyang Technological University, Singapore (NTU Singapore) and its innovation and enterprise company, NTUitive; and Singapore Institute of Technology (SIT) to boost Singapore's biologics manufacturing capabilities. more info >> |
|
| Thursday, June 2, 2022 |
|
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. more info >> |
|
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| more info >> |
|
| Thursday, September 30, 2021 |
|
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for the vaccination centres which are set up by the Ministry of Health and operated by private healthcare providers. more info >> |
|
| Friday, July 31, 2020 |
|
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving "First Patient First Visit[1]" in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers. more info >> |
|
| Friday, July 24, 2020 |
|
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| MP Biomedicals Asia Pacific Pte Ltd, a diagnostic corporation which has been operating for over 30 years focusing on various infectious disease testing development and manufacturing, today announced the successful development of a rapid antibody test kit for COVID-19, in collaboration with the Agency for Science, Technology and Research (A*STAR). more info >> |
|
| Tuesday, October 22, 2019 |
|
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| Fujitsu Limited, the Singapore Management University (SMU) and the Agency for Science, Technology and Research (A*STAR)'s Institute of High Performance Computing today announced the launch of the Digital Platform Experimentation Project. more info >> |
|
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| Fujitsu Limited, the Singapore Management University (SMU) and the Agency for Science, Technology and Research (A*STAR)'s Institute of High Performance Computing today announced the launch of the Digital Platform Experimentation Project. more info >> |
|
| Monday, October 21, 2019 |
|
|
富士通・シンガポール科学技術庁・Singapore Management University、「デジタルアニーラ」とディープラーニング技術を活用したプロジェクトを開始 |
| 富士通株式会社とシンガポール科学技術庁のハイパフォーマンスコンピューティング研究所（Institute of High Performance Computing）、およびSingapore Management Universityはこのたび、「FUJITSU Quantum-Inspired Computing Digital Annealer」とディープラーニング技術を活用したデジタルプラットフォーム実装プロジェクトを開始します。 more info >> |
|
| Friday, June 28, 2019 |
|
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| The nation's drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors
Jan 23, 2025 11:00: JST
|
|
|
日本総合研究所と富士通が、三井住友銀行のシステムバージョンアップに生成AIを用いた共同実証で生産性向上を実現
Jan 23, 2025 10:15: JST
|
|
|
ZeroPath 公司推出下一代代碼安全平台，結合人工智慧技術
Jan 23, 2025 10:00 HKT/SGT
|
|
|
ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence
Jan 23, 2025 10:00 HKT/SGT
|
|
|
다나까귀금속공업, 전력반도체용 시트형상 접합 재료 ‘AgSn TLP 시트’ 개발
Jan 23, 2025 10:00 HKT/SGT
|
|
|
田中貴金屬工業開發出適用於功率半導體的片狀接合材料「AgSn TLP片」
Jan 23, 2025 10:00 HKT/SGT
|
|
|
田中贵金属工业开发了面向功率半导体的片状接合材料“AgSn TLP片”
Jan 23, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors
Jan 23, 2025 11:00 JST
|
|
|
Tamkeen Launches 'Bahrain Skills and Gender Parity Accelerator' at Davos
Jan 23, 2025 08:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY
Jan 22, 2025 21:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) 旗下子公司 Green Rain Solar Inc. 探討在紐約州希臘鎮出售太陽能農場開發權
Jan 22, 2025 21:00 HKT/SGT
|
|
|
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST
|
|
|
2nd Annual Operational Excellence & Business Transformation Summit: Operational Excellence in The Age of Digital Transformation, Building A Sustainable and Collaborative Future in Asia
Jan 22, 2025 16:15 HKT/SGT
|
|
|
Introducing the Sonim XP400: a 5g Smartphone Engineered for Demanding Days with Unmatched Durability, Now Available in EMEA and Australia
Jan 22, 2025 15:09 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
